Contact
Privacy Policy
Term of Use
Purchase Terms
COVID-19 Statement

Company
- About
- Leadership
- Partnering
- Contact
Focus
Programs
Careers
- Job Openings
- Life at Aeglea
Investors & Media
Patients & Families

Select Page

Development of a Novel Human Engineered Enzyme (ACN00177) for the Treatment of Homocystinuria

by aegleawebdev | Oct 27, 2020

Search

Recent Comments

Company

About
Leadership
Partnering
Contact

Focus

Enzyme Therapeutics
Rare Metabolic Disease
Publications

Programs

Pipeline
Pegtarviliase
Pegzilarginase
Clinical Trials

Careers

Job Openings
Life at Aeglea

Investors & Media

Company Overview
Press Releases
Events & Presentations
Stock Information
Financials
Corporate Governance
Resources

Patients & Families

Overview
Homocystinuria
Arginase 1 Deficiency
Diet & Nutrition
Clinical Trials FAQs

© 2023 Aeglea BioTherapeutics. Privacy Policy Terms of Use Purchase Terms COVID-19 Statement

Welcome
About ARG1-D
Diagnosing ARG1-D
Managing ARG1-D
Patient Advocacy
Connect